Cargando…

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer

The clinical features and prognosis of breast cancer can vary widely, depending on the molecular subtype. Luminal B breast cancers are usually either estrogen receptor-positive and/or progesterone receptor-positive with high proliferation of Ki67 index, or HER2 positive (HER2+). The authors compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Byeongju, Lee, Jeeyeon, Jung, Jin Hyang, Kim, Wan Wook, Keum, Heejung, Park, Ho Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470803/
https://www.ncbi.nlm.nih.gov/pubmed/37653831
http://dx.doi.org/10.1097/MD.0000000000034772
_version_ 1785099763526402048
author Kang, Byeongju
Lee, Jeeyeon
Jung, Jin Hyang
Kim, Wan Wook
Keum, Heejung
Park, Ho Yong
author_facet Kang, Byeongju
Lee, Jeeyeon
Jung, Jin Hyang
Kim, Wan Wook
Keum, Heejung
Park, Ho Yong
author_sort Kang, Byeongju
collection PubMed
description The clinical features and prognosis of breast cancer can vary widely, depending on the molecular subtype. Luminal B breast cancers are usually either estrogen receptor-positive and/or progesterone receptor-positive with high proliferation of Ki67 index, or HER2 positive (HER2+). The authors compared the clinicopathologic factors and survival rates of different subtypes of luminal B breast cancer according to HER2 status. Between 2009 and 2013, 1131 cases of breast cancer were reviewed and characterized as 1 of 4 different molecular subtypes based on their immunohistochemical results: luminal A, luminal B, HER2+, or triple-negative breast cancer. From these, luminal B breast cancers were extracted and the clinical features and prognosis of the HER2- and the HER2 + subtypes were compared. Survival differed significantly based on the molecular subtype regardless of whether or not the patient received treatment with neoadjuvant chemotherapy. While patients with HER2- luminal B breast cancer who received neoadjuvant chemotherapy had better prognoses, patients with HER2 + luminal B breast cancer who did not receive neoadjuvant chemotherapy had better prognoses. Luminal B breast cancers showed different clinical outcomes and survival rates according to HER2 gene overexpression type. Physicians should consider these results when they establish a treatment strategy.
format Online
Article
Text
id pubmed-10470803
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104708032023-09-01 Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer Kang, Byeongju Lee, Jeeyeon Jung, Jin Hyang Kim, Wan Wook Keum, Heejung Park, Ho Yong Medicine (Baltimore) 5700 The clinical features and prognosis of breast cancer can vary widely, depending on the molecular subtype. Luminal B breast cancers are usually either estrogen receptor-positive and/or progesterone receptor-positive with high proliferation of Ki67 index, or HER2 positive (HER2+). The authors compared the clinicopathologic factors and survival rates of different subtypes of luminal B breast cancer according to HER2 status. Between 2009 and 2013, 1131 cases of breast cancer were reviewed and characterized as 1 of 4 different molecular subtypes based on their immunohistochemical results: luminal A, luminal B, HER2+, or triple-negative breast cancer. From these, luminal B breast cancers were extracted and the clinical features and prognosis of the HER2- and the HER2 + subtypes were compared. Survival differed significantly based on the molecular subtype regardless of whether or not the patient received treatment with neoadjuvant chemotherapy. While patients with HER2- luminal B breast cancer who received neoadjuvant chemotherapy had better prognoses, patients with HER2 + luminal B breast cancer who did not receive neoadjuvant chemotherapy had better prognoses. Luminal B breast cancers showed different clinical outcomes and survival rates according to HER2 gene overexpression type. Physicians should consider these results when they establish a treatment strategy. Lippincott Williams & Wilkins 2023-08-25 /pmc/articles/PMC10470803/ /pubmed/37653831 http://dx.doi.org/10.1097/MD.0000000000034772 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5700
Kang, Byeongju
Lee, Jeeyeon
Jung, Jin Hyang
Kim, Wan Wook
Keum, Heejung
Park, Ho Yong
Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
title Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
title_full Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
title_fullStr Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
title_full_unstemmed Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
title_short Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
title_sort differences in clinical outcomes between her2-negative and her2-positive luminal b breast cancer
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470803/
https://www.ncbi.nlm.nih.gov/pubmed/37653831
http://dx.doi.org/10.1097/MD.0000000000034772
work_keys_str_mv AT kangbyeongju differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer
AT leejeeyeon differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer
AT jungjinhyang differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer
AT kimwanwook differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer
AT keumheejung differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer
AT parkhoyong differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer